ganciclovir and foscarnet were administered to the left eye in conjunction with systemic antiviral therapy with intravenous foscarnet and ganciclovir. Subsequently, there was significant improvement in left retina with no evidence of active inflammation and four weeks later his CMV load in both plasma and CSF was undetectable. CD4 count increased to 90 cells/mL. Intravenous foscarnet monotherapy was continued for a further four weeks until CD4 count rose above 100 cells/mL. This is a case of difficult-to-treat recurrent CMV retinitis. In the published 1 case, the use of oral valganciclovir given after receiving aggressive treatment (including three weeks of intravenous ganciclovir) was unable to prevent recurrence of CMV retinitis. Similarly, in the present case, CMV recurred after 10 weeks of appropriate treatment and resistance was detected in peripheral blood. We remain unsure as to why we were unable to detect resistance mutations in the CSF despite the high CMV load. When intravenous foscarnet was combined with ganciclovir there was significant reduction in CMV load and retinal improvement, in keeping with the experience of Adler et al. It is known that 3 maintenance therapy should be continued until CD4 >100 cells/mL and HIV viral load is undetectable; this posed a challenge in our case as immune reconstitution was very slow, possibly in part due to previous chemotherapy. This resulted in a prolonged hospital admission that was further complicated by an episode of line sepsis, possibly related to the prolonged use of intravenous ganciclovir, which itself can cause myelosuppression. 4 This report demonstrates the difficulties that may be faced when managing CMV retinitis in severely immunocompromised patients who are slow to immune reconstitution. There is risk of recurrent CMV retinitis, the management of which is problematic as effective treatment is needed, whilst avoiding further complications of developing resistance and the adverse effects of antivirals. It highlights the question of how long patients should continue on maintenance therapy if immune reconstitution is slow to progress. There has been found to be a correlation between CMV DNA levels becoming detectable and the progression of CMV retinitis in patients receiving maintenance therapy with ganciclovir. 5 One option may be to monitor CMV DNA levels whilst on maintenance therapy and switching to a treatment dose if they become detectable. However, greater experience in the management of similar cases will be needed in order to establish an answer to this question.
